Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer

Background:[18F]fluorothymidine (FLT) has been proposed as a positron emission tomography (PET)-imaging biomarker of proliferation for breast cancer. The aim of this prospective study was to assess the feasibility of FLT-PET-CT as a technique for predicting the response to neoadjuvant chemotherapy (NAC) in primary breast cancer and to compare baseline FLT with Ki-67.Methods:Twenty women with primary breast cancer had a baseline FLT-PET-CT scan that was repeated before the second cycle of chemotherapy. Expression of Ki-67 in the diagnostic biopsy was quantified. From the FLT-PET-CT scans lesion maximum and mean standardised uptake values (SUVmax, SUVmean) were calculated.Results:Mean baseline SUVmax was 7.3, and 4.62 post one cycle of NAC, representing a drop of 2.68 (36.3%). There was no significant association between baseline, post chemotherapy, or change in SUVmax and pathological response to NAC. There was a significant correlation between pre-chemotherapy Ki-67 and SUVmax of 0.604 (P=0.006).Conclusions:Baseline SUVmax measurements of FLT-PET-CT were significantly related to Ki-67 suggesting that it is a proliferation biomarker. However, in this series neither the baseline value nor the change in SUVmax after one cycle of NAC were able to predict response as most patients had a sizeable SUVmax reduction.

[1]  R. Boellaard,et al.  Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With Erlotinib , 2012, Clinical nuclear medicine.

[2]  N. Satyamurthy,et al.  RESEARCH A RTICLE Usefulness of 3 0 -(F-18)Fluoro-3 0 -deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2006 .

[3]  M. Bergström,et al.  Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective. , 2009, Current pharmaceutical design.

[4]  Mark Muzi,et al.  Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Dimitris Visvikis,et al.  Reproducibility of 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Tumor Volume Measurements , 2010, The Journal of Nuclear Medicine.

[6]  H. Malcolm Hudson,et al.  Accelerated image reconstruction using ordered subsets of projection data , 1994, IEEE Trans. Medical Imaging.

[7]  Robert Jeraj,et al.  Impact of Different Standardized Uptake Value Measures on PET-Based Quantification of Treatment Response , 2013, The Journal of Nuclear Medicine.

[8]  A. Shields,et al.  PET Imaging of Proliferation with Pyrimidines , 2013, The Journal of Nuclear Medicine.

[9]  Mitch Dowsett,et al.  Current and emerging biomarkers in breast cancer: prognosis and prediction. , 2010, Endocrine-related cancer.

[10]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[11]  Eric O. Aboagye,et al.  Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  S. Shousha,et al.  Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. , 2005, Cancer research.

[13]  R. Boellaard,et al.  Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Ronald Boellaard,et al.  Effects of Image Characteristics on Performance of Tumor Delineation Methods: A Test–Retest Assessment , 2011, The Journal of Nuclear Medicine.

[15]  R. Boellaard,et al.  Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET , 2011, The Journal of Nuclear Medicine.

[16]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[17]  P. Marsden,et al.  Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. , 2012, European journal of cancer.

[18]  Robin L. Jones,et al.  The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.

[19]  O. Muzik,et al.  Analysis and Reproducibility of 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[20]  M. Lubberink,et al.  Validity of Simplified 3′-Deoxy-3′-[18F]Fluorothymidine Uptake Measures for Monitoring Response to Chemotherapy in Locally Advanced Breast Cancer , 2012, Molecular Imaging and Biology.

[21]  Michael E Phelps,et al.  Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. , 2006, Chest.

[22]  V. Pike,et al.  An improved synthesis of 3′-DEOXY-3′-[18F]fluorothymidine ([18F]FLT) and the fate of the precursor, 2, 3′-anhydro-5′-O-(4, 4′-dimethoxytrityl)-thymidine , 2001 .

[23]  F. Zeman,et al.  Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry , 2013, Breast Cancer Research and Treatment.

[24]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[25]  R. Boellaard,et al.  Reproducibility of quantitative 18 F-3 ′-deoxy-3 ′-fluorothymidine measurements using positron emission tomography , 2009 .

[26]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[27]  Lale Kostakoglu,et al.  Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck. , 2008, International journal of radiation oncology, biology, physics.

[28]  R. Boellaard,et al.  Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  A. Lammertsma,et al.  [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study , 2008, British Journal of Cancer.

[30]  Michael E. Phelps,et al.  Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.

[31]  Mitch Dowsett,et al.  Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Torsten Mattfeldt,et al.  Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  H. Barthel,et al.  Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. , 2006, Cancer research.

[34]  T. Lehnert,et al.  Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET , 2007, Leukemia & lymphoma.

[35]  John L. Humm,et al.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[36]  Markus Schwaiger,et al.  Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. , 2009, Methods.

[37]  Gerald Reischl,et al.  PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  Shankar Vallabhajosula,et al.  (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. , 2007, Seminars in nuclear medicine.

[39]  Takashi Nakajima,et al.  Evaluation of thoracic tumors with 18F‐FMT and 18F‐FDG PET‐CT: A clinicopathological study , 2009, International journal of cancer.

[40]  Fiona J Gilbert,et al.  Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Tushar C. Barot,et al.  The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  S. Shousha,et al.  Biological basis of [11C]choline-positron emission tomography in patients with breast cancer: comparison with [18F]fluorothymidine positron emission tomography , 2011, Nuclear medicine communications.